Amlodipine And Atorvastatin Tablet, Film Coated
Product Images NDC 71335-3076

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Amlodipine And Atorvastatin (NDC 71335-3076). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Amlodipine Besylate And Atorvastatin Calcium 02)

This is a Kaplan-Meier event rate plot comparing Amlodipine and Placebo over a 24-month period. The y-axis shows event rate, and the x-axis shows time in months. The plot includes statistical data: P-value 0.003, hazard ratio 0.691, and 95% confidence interval (0.54, 0.88). It displays the number of subjects at risk at various time points.*

FDA Label Image

Figure 2 (Amlodipine Besylate And Atorvastatin Calcium 03)

A forest plot chart depicting hazard ratios with 95% confidence intervals comparing Amlodipine versus placebo across various subgroups, including age, gender, baseline systolic blood pressure, baseline vessel disease, vessel stenosis, and PCI-stent strata. It visually represents the favorability of Amlodipine or placebo along the horizontal axis.*

FDA Label Image

Figure 3 (Amlodipine Besylate And Atorvastatin Calcium 04)

A line graph showing cumulative incidence percentage over time in years, comparing Atorvastatin and placebo groups. The solid line represents Atorvastatin, which shows a lower cumulative incidence than the dashed line representing placebo, with a hazard ratio and p-value indicated on the graph.*

FDA Label Image

Figure 4 (Amlodipine Besylate And Atorvastatin Calcium 05)

A line graph showing cumulative hazard percentage over time for Atorvastatin versus placebo. The x-axis represents years of follow-up up to 5 years, and the y-axis shows cumulative hazard percentage up to 15%. Two lines compare Placebo (dashed) and Atorvastatin (solid), with Atorvastatin consistently lower. A hazard ratio and p-value (HR 0.63, p=0.001) are noted in the graph.*

FDA Label Image

Figure 5 (Amlodipine Besylate And Atorvastatin Calcium 06)

A line graph comparing the percentage of subjects experiencing a cardiovascular event over time between two atorvastatin doses (10 mg and 80 mg). The x-axis represents time to first major cardiovascular endpoint in years (0 to 5), and the y-axis shows the percentage of subjects experiencing the event (0 to 0.2%). The 10 mg group is represented by a dotted line, and the 80 mg group by a solid line, showing lower event rates over time for the 80 mg group.*

FDA Label Image

Amlodipine (Amlodipine)

Chemical structure diagram showing molecular components, one with a chlorine-substituted benzene ring and various functional groups including ester, amide, and amine groups, and another with a benzene ring bonded to a sulfonic acid group. The structures likely represent components of Amlodipine and Atorvastatin.*

FDA Label Image

Atorvastatin-glycol-solvate (Atorvastatin Glycol Solvate)

Chemical structure diagram of the active ingredients Amlodipine and Atorvastatin, showing their molecular components and calcium salt form associated with atorvastatin.*

FDA Label Image

Label (Lbl713353076)

Label for Amlodipine and Atorvastatin Tablets USP, 10 mg/10 mg film-coated tablets. The package contains 30 tablets. It is labeled as prescription only with NDC 71335-3076-1. The label indicates the product is repackaged by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by Apotex Inc. Storage instructions and child-resistant container warning are also present.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.